Skip to main content

Table 1 Eligibility Criteria

From: Association between furosemide in premature infants and sensorineural hearing loss and nephrocalcinosis: a systematic review

Patient/Population

Infant < 37 weeks completed gestational age

Intervention

≥1 dose of furosemide (IV or PO) during hospitalization in the neonatal intensive care unit

Control

Infant < 37 weeks completed gestational age without exposure to furosemide

Outcomes

sensorineural hearing loss; nephrocalcinosis/nephrolithiasis

Study Design

clinical trials, retrospective or prospective cohort studies, case-control studies